Wenger NK - Search Results

1

Design and methods of the Raloxifene Use for The Heart (RUTH) study.

Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW. Mosca L, et al. Among authors: wenger nk. Am J Cardiol. 2001 Aug 15;88(4):392-5. doi: 10.1016/s0002-9149(01)01685-x. Am J Cardiol. 2001. PMID: 11545760

2

Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop.

Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Manolio TA, et al. Among authors: wenger nk. Ann Epidemiol. 1992 Jan-Mar;2(1-2):161-76. doi: 10.1016/1047-2797(92)90051-q. Ann Epidemiol. 1992. PMID: 1342259

3

Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene.

Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, Cox DA, Moscarelli E, Anderson PW. Barrett-Connor E, et al. Among authors: wenger nk. J Womens Health. 1998 Sep;7(7):839-47. doi: 10.1089/jwh.1998.7.839. J Womens Health. 1998. PMID: 9785310 Review.

4

Coronary heart disease in women, randomized clinical trials, HERS and RUTH.

Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, Cox DA, Moscarelli E, Anderson PW. Barrett-Connor E, et al. Among authors: wenger nk. Maturitas. 1998 Nov 30;31(1):1-7. doi: 10.1016/s0378-5122(98)00099-1. Maturitas. 1998. PMID: 10091198 No abstract available.

5

Postmenopausal hormone therapy, SERMs, and coronary heart disease in women.

Wenger NK, Grady D. Wenger NK, et al. J Endocrinol Invest. 1999 Sep;22(8):616-24. doi: 10.1007/BF03343619. J Endocrinol Invest. 1999. PMID: 10532249 Review. No abstract available.

6

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.

Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Grady D, et al. Among authors: wenger nk. Ann Intern Med. 2000 May 2;132(9):689-96. doi: 10.7326/0003-4819-132-9-200005020-00002. Ann Intern Med. 2000. PMID: 10787361 Clinical Trial.

7

Hormone Replacement Therapy in Postmenopausal Women: Does It Lessen Coronary Heart Disease Risk?

Wenger NK. Wenger NK. Am J Geriatr Cardiol. 1996 Oct;5(5):71-76. Am J Geriatr Cardiol. 1996. PMID: 11416395

8

Hormonal and Nonhormonal Therapies for the Postmenopausal Woman: What is the Evidence for Cardioprotection?

Wenger NK. Wenger NK. Am J Geriatr Cardiol. 2000 Jul;9(4):204-209. doi: 10.1111/j.1076-7460.2000.80039.x. Am J Geriatr Cardiol. 2000. PMID: 11416567

9

Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, Schenck-Gustafsson K, Smith SC Jr, Taubert KA, Wenger NK; American Heart Association. Mosca L, et al. Among authors: wenger nk. Circulation. 2001 Jul 24;104(4):499-503. doi: 10.1161/hc2901.092200. Circulation. 2001. PMID: 11468217 No abstract available.

10

Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease.

Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD; Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Shlipak MG, et al. Among authors: wenger nk. J Am Coll Cardiol. 2001 Sep;38(3):705-11. doi: 10.1016/s0735-1097(01)01450-4. J Am Coll Cardiol. 2001. PMID: 11527621 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

610 results

Search Page

Filters